Home > Insider Trading > Filing (0001140361-14-025611)

Filing Details

Accession Number:: 0001140361-14-025611
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-06-13 16:16:21
Reporting Period:: 2014-06-11

Filing Date:: 2014-06-13
Accepted Time:: 2014-06-13 16:16:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1428522	Radius Health Inc.	RDUS	Blank Checks (6770)	800145732

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1575748	Katherine Priestley	Suite 6, Albion Riverside Building 8 Hester Road London X0 SW11 4AX	No	No	Yes	No
1575753	Ltd Capital F2	3Rd Floor, Geneve Place, Waterfront Dr Po Box 3175, Road Town Tortola D8	No	No	Yes	No
1600630	L.p. Iv Bioscience F2	Po Box 309, Ugland House South Church Street George Town E9 KY1-1104	No	No	Yes	No
1600632	Ltd. Gp Iv Bioscience F2	Po Box 309, Ugland House South Church Street George Town E9 KY1-1104	No	No	Yes	No
1600634	L.p. V Ventures Bio F2	Kingston Chambers, P.o. Box 173 Road Town Tortola D8	No	No	Yes	No
1600635	Ltd. Gp Ventures Bio F2	Kingston Chambers, P.o. Box 173 Road Town Tortola D8	No	No	Yes	No
1600769	Ltd Holdings Globeways	3Rd Floor, Geneve Place, Waterfront Dr Po Box 3175, Road Town Tortola D8	No	No	Yes	No
1610441	L.p. Vi Bioscience F2	Po Box 309, Ugland House South Church Street George Town E9 KY1-1104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-06-11	1,794,983	$0.00	1,794,983	No	4	C	Direct
Common Stock	Acquisiton	2014-06-11	871,851	$0.00	871,851	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2014-06-11	587,500	$8.00	587,500	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-2 Convertible Preferred Stock	Disposition	2014-06-11	227,938	$0.00	1,794,983	$0.00
Common Stock	Series B-2 Convertible Preferred Stock	Disposition	2014-06-11	110,713	$0.00	871,851	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Indirect

Footnotes

The securities reported reflect (i) the total number of shares of common stock issued pursuant to the conversion of Series B-2 Convertible Preferred Stock (the "Series B-2 Stock") previously reported, (ii) a 1 for 2.28 reverse stock split, effected by the Issuer on 4/24/14 (the "Stock Split"), and (iii) all accrued dividends on the Series B-2 Stock paid in shares of common stock in connection with such conversion.
The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 IV"). F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The reported securities are owned directly by F2 Bioscience VI L.P. ("F2 Science"). F2 IV GP is the General Partner of F2 Science. Katherine Priestley and Globeways are members of F2 IV GP. F2 Capital is an investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Prior to its automatic conversion into common stock upon the closing of the Issuer's initial public offering on June 11, 2014 (the "Closing Date"), the Series B-2 Stock was convertible at any time, at the holder's election and had no expiration date. On the Closing Date, the Series B-2 Stock was automatically converted into common stock on a 4.386 to 1 basis (which conversion ratio is reflective of the Stock Split), plus accrued dividends on the Series B-2 Stock payable in shares of common stock in connection with such conversion.